Interestingly, ALDH and IL‐1 receptor (IL1R1) double‐positive CSCs are enriched following antiestrogen therapy and held responsible for the treatment failure in breast cancer patients, which can be attenuated with IL1R1 antagonists such as anakinra.290. Here, IL1R1 is linked to breast cancer.